BGM Group Ltd. Class A (BGM)
NASDAQ: BGMHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
BGM stock chart
Technical analysisKey statistics
All statistics- Market cap
- $108.57M
- EPS (TTM)
- -$4.80
- Dividend yield
- None
- Ex-dividend date
- Feb 27, 2023
- 52-week range
- 0.00 – 263.70
- Day range
- 0.00 – 0.00
- Volume / Avg
- 127 / 6.18K
- Beta
- —
- Shares outstanding
- 12.69M
52-week range
BGM stock today
BGM Group (BGM) closed at $8.13 on Nov 20, essentially unchanged from the prior close, versus the S&P 500's 3.70% decline. Trading was light, with 127 shares changing hands, about 2% of the average daily volume. At this level, BGM sits near the bottom of its 52-week range of $0.00 to $263.70: 96.9% below the high, set on Nov 24, 2025 and 0.0% above the low.
BGM is down 92.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 96.7%. BGM Group has posted a net loss over the last twelve months (EPS of -$4.80), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About BGM Group
Company profileBGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. The company operates through Diversified Pharmaceutical and Allied Products; AI Solution; and Insurance Business segments. It offers oxytetracycline products, including Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline active pharmaceutical ingredients, which are used by pharmaceutical companies in the manufacturing of medications that use oxytetracycline as an active ingredient.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Ms. Huandi Zhao
- Headquarters
- Chengdu
- IPO year
- 2021
- Website
- bgmgroupltd.com
Financial highlights
Full financialsIn fiscal 2025, BGM Group generated $37.9 million in revenue, up 51.1% from fiscal 2024. BGM Group reported a net loss of $19.9 million, compared with a loss of $1.4 million a year earlier. Gross margin was 16.6% (up from 16.4%) and operating margin -33.2%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $37.92M | $25.10M | $46.47M | $64.86M | $57.10M |
| Growth | +51.09% | -45.99% | -28.35% | +13.58% | +14.12% |
| Net income | $-19.94M | $-1.44M | $-7.78M | $1.08M | $3.15M |
| EPS (diluted) | $-0.18 | $-0.20 | $-1.08 | $0.15 | $0.09 |
Dividends
Dividend history- Annual dividend
- $0.00
- Last payment
- $7.50
- Ex-dividend date
- Feb 27, 2023
BGM Group peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SPRBSpruce Biosciences Inc. | 38.00 | -6.15% | $109.21M | vs BGM |
| AKBAAkebia Therapeutics Inc. | 0.3855 | -8.71% | $107.04M | vs BGM |
| MENSJyong Biotech Ltd. | 1.45 | -17.14% | $110.24M | vs BGM |
| IMUXImmunic Inc. | 6.99 | -5.41% | $111.01M | vs BGM |
| OKUROnKure Therapeutics Inc. Class A | 2.70 | -2.17% | $111.21M | vs BGM |
| GNLXGenelux Corporation | 2.17 | -4.82% | $103.36M | vs BGM |
| FHTXFoghorn Therapeutics Inc. | 1.72 | -3.37% | $103.14M | vs BGM |
| ORGOOrganogenesis Holdings Inc. Class A | 0.7716 | -2.23% | $100.16M | vs BGM |
Indexes, lists and sector
BGM Group stock FAQ
What is BGM Group's stock price today?
BGM last traded at $8.13 as of Nov 20, 4:00 PM EST, up 0.00% on the day. Prices are delayed at least 15 minutes.
Does BGM Group pay a dividend?
Yes. BGM Group pays $0.00 per share annually. The most recent dividend of $7.50 had an ex-dividend date of Feb 27, 2023.
Who is BGM Group's CEO?
Ms. Huandi Zhao is the chief executive officer of BGM Group Ltd. Class A.
Has BGM ever split its stock?
Yes. The most recent BGM stock split was a 1-for-30 split on Oct 1, 2026, one of 2 splits on record.
What is the BGM 52-week high?
The 52-week high for BGM is $263.70 and the 52-week low is $0.00. The stock is currently 96.9% below its high.